These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18673235)

  • 1. Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy.
    Longstaff C; Williams S; Thelwell C
    Cardiovasc Hematol Agents Med Chem; 2008 Jul; 6(3):212-23. PubMed ID: 18673235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
    Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
    Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
    Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The fibrinolytic system and its activators].
    Seifried E
    Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units.
    Longstaff C; Whitton CM
    J Thromb Haemost; 2004 Aug; 2(8):1416-21. PubMed ID: 15304049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in thrombolytic therapy.
    Collen DC; Gold HK
    Thromb Res Suppl; 1990; 10():105-31. PubMed ID: 2180114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Third-generation thrombolytic drugs.
    Verstraete M
    Am J Med; 2000 Jul; 109(1):52-8. PubMed ID: 10936478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel and emerging therapies: thrombus-targeted fibrinolysis.
    Lippi G; Mattiuzzi C; Favaloro EJ
    Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
    Pannell R; Li S; Gurewich V
    J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remaining perspectives of mutant and chimeric plasminogen activators.
    Lijnen HR; Collen D
    Ann N Y Acad Sci; 1992 Dec; 667():357-64. PubMed ID: 1309056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fibrinolytic system in man.
    Collen D; Lijnen HR
    Crit Rev Oncol Hematol; 1986; 4(3):249-301. PubMed ID: 2420482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thrombolytics and their use].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.
    Hoffmeister HM; Kastner C; Szabo S; Beyer ME; Helber U; Kazmaier S; Baumbach A; Wendel HP; Heller W
    Am J Cardiol; 2000 Aug; 86(3):263-8. PubMed ID: 10922430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
    Gram J
    Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The search for the ideal thrombolytic agent.
    Verstraete M
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolytic therapy.
    Collen D; Stump DC; Gold HK
    Annu Rev Med; 1988; 39():405-23. PubMed ID: 3130773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
    Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.